Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Vertex Pharmaceuticals ( (VRTX) ) is now available.
On April 28, 2026, Vertex Pharmaceuticals said director Suketu Upadhyay informed its board that he would not stand for re‑election at the company’s 2026 annual meeting, as he has been named the forthcoming chief financial officer of Incyte Corporation and faces scheduling conflicts. Upadhyay, who will serve on the board until the meeting and has no disagreements with Vertex on operations or policies, will be removed from the proxy slate, prompting the board to reduce its size to ten members while keeping the remaining director nominees and all previously submitted proxies—other than votes for Upadhyay—intact for the 2026 shareholder vote.
The most recent analyst rating on (VRTX) stock is a Hold with a $441.00 price target. To see the full list of analyst forecasts on Vertex Pharmaceuticals stock, see the VRTX Stock Forecast page.
Spark’s Take on VRTX Stock
According to Spark, TipRanks’ AI Analyst, VRTX is a Outperform.
The score is supported by strong fundamentals (high margins, solid 2025 profitability, conservative leverage) and a constructive earnings outlook with 2026 growth guidance and advancing launches/pipeline. It is held back by weak current technical momentum and the company’s recent volatility in earnings and cash flow (notably the 2024 downturn) alongside near-term margin/tax headwinds from higher 2026 investment and a higher expected tax rate.
To see Spark’s full report on VRTX stock, click here.
More about Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company focused on developing and commercializing therapies for serious diseases, particularly in areas such as cystic fibrosis and other specialty conditions. The company operates in the biopharmaceutical industry, targeting high‑unmet‑need patient populations with innovative, often highly specialized treatments.
Average Trading Volume: 1,364,599
Technical Sentiment Signal: Sell
Current Market Cap: $108.4B
Learn more about VRTX stock on TipRanks’ Stock Analysis page.